Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Mucosis, Crucell In Research Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Mucosis, Crucell In Research Pact

Will use Mimopath platform for vaccine development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Mucosis BV has signed a research and license option agreement with Crucell Holland B.V., under which Crucell will use Mucosis’ Mimopath platform technology to develop vaccines for infectious diseases. Mucosis will receive upfront payments and is eligible to receive achievement-based milestones. Financial terms were not disclosed.
 
“We are delighted to collaborate with Crucell as we strongly believe that our Mimopath platform combined with Crucell’s expertise in vaccine development create a substantial opportunity to develop differentiated and medically relevant vaccine candidates,” said Thomas Johnston, chief executive officer of Mucosis. “We are proud of the progress we’ve made to date in developing the Mimopath platform, including our recent positive human clinical trials. We see this agreement as a further validation of our platform and its potential to combat infectious diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics